


Ground Breaking Cancer Treatment: Tumors Vanish Within Few Days



synergymed-ltd.com Boston, MA

Highlights

- 1 Successful studies on mice and dogs
- 2 Aim to enter veterinary market by Q4 2024. Targeting FDA approval & human commercialization by 2026
- 3 \$0.5 Billion projected revenue within 5 years (not guaranteed)
- 4 Received awards and recognitions from 6 national and international startup competitions and events
- 5 Patent-pending technology
- 6 Available CPT Codes for reimbursement by Medicare and



commercial insurances



7 Commercial product near completion and certification



8 Building collaborations with leading U.S. institutions (Tufts, Harvard, ...)

Featured Investor



Teresa Cornella
Syndicate Lead

Follow

Invested \$5,000 

“Cancer treatment has long been associated with daunting procedures, lengthy recovery periods, and a profound impact on quality of life. Traditional surgery, while often effective, can be invasive and painful, leaving patients and their families searching for better alternatives. In this landscape, SynergyMed stands out as a beacon of hope, offering a revolutionary approach to cancer treatment. SynergyMed” precise, noninvasive methodology marks a significant leap forward in oncology. Their cutting edge technology focuses on treating tumors with exceptional accuracy, limiting collateral damage to surrounding healthy tissue. This precision is not just a technological advancement. It represents a fundamental shift in patient care. For patients, this means a treatment option that drastically reduces the physical and emotional burden typically associated with cancer surgery. I am excited to support SynergyMed and their groundbreaking work in revolutionizing cancer treatment. Their precise, non-invasive approach to treating tumors is a game-changer. By eliminating the pain and invasiveness of traditional surgery, SynergyMed aims to transform cancer care.”

Our Team



Anan Coptly CEO

25+ years of technical & leadership experiences, RMD: Radiation Monitoring Devices, Intel: Biochips, Harvard Medical School: MRI



Yahya Dajani VP of Business Development

Medical Technology Entrepreneur. Co-founded NCA Monitoring Technologies & D&O LLC ADNOC Oil Company Corporate Planning, Finance, Performance, and Business Development



Daniel Kacher, Ph.D. Director of Clinical Studies and Product Development

Ph.D. in Biomedical Engineering 25 years at Brigham and Women's Hospital



Robert Roy, MBA, BSEE/BSME VP of Marketing, Sales

35+ years of senior-level management in medical device companies



Mimi Copt, MHA COO

25+ years of project management & leadership experiences in health organizations in the US and internationally

The Non-Surgical 10 Min Solution to Destroy Cancer Tumors




SynergyMed

The non-surgical
solution for treatment
of cancer tumors



SynergyMed Devices Inc.



We've developed a groundbreaking, **noninvasive** medical device and technology that destroyed cancer tumors in as little as **three days** in Animals.

In a single, **ten-minute** treatment session, our precise technology can treat tumors without damaging surrounding healthy tissue, causing cosmetic deformities and scars, or affecting the patient's quality of life.

About Company

SynergyMed Devices Inc is a medical device company developing a non-invasive electromagnetic ablation systems for the treatment of cancerous tumors as an alternative to surgery for the human and veterinary markets.





Problem

Surgery is Risky and
Impacts the Quality of Life

Risks of Surgery

- Impacts the quality of life for patients
- For brain cancers including Glioblastoma, surgery is not always possible.
- Can have a severe effect on patient's lifestyle with tongue (head & neck) cancer
- Re-Excision of tumors for 10-40% of breast cancer surgeries
- 75% of lung cancer patients are non-surgical candidates.
- Cosmetic risks

Cost Prohibitive

- Surgery is expensive and requires a lot of follow ups including re-excisions at times.

No Viable Alternative Technology

Conventional ablation devices

- require image guidance
- damage healthy tissue
- lack feedback mechanisms
- lack treatment dose evaluation.

Today, the most common treatment for early-stage solid cancer tumor patients is surgery.

But, surgery, while effective, may significantly **impact quality of life, come with many risks and a long recovery time.**

Some of these risks include:

- Bleeding
- Infections
- Restricted range of movement
- Resection and amputation
- In case of breast tumors, removal of breasts and other surrounding healthy tissue
- Nerve pain or numbness
- Cosmetic deformities
- Anesthesia risks
- Organ failure

- And even death

In some cases, surgery is not even possible.

Some examples include:

- Age
- Diabetes
- Location of tumor
- Chronic diseases or heart problems

Solution

A Noninvasive Ablation Device



Mouse experiment showing complete disappearance of cancer tumors within 3 days using SynergyMed's noninvasive technology, with no visible damage to surrounding tissue.

**Disruptive Patented
Technologies**

- Tailored RF and MW
applicators

applicators

- FDA/CE approved nanoparticles
- Proprietary Algorithms

Animal Studies Results


- Within 3 -5 days the tumor volume diminishes to zero
- Rapid, definitive treatment: Single 10-minute treatment
- No cosmetic damage
- Fewer follow ups
- Improved quality of life
- Less recovery time

Cost Optimized

- 2x less than surgery
- 3x less time per procedure. More time to help more patients
- Treat several tumors simultaneously
- No costly online image guidance (e.g. MRI)

Our goal is to put an end to painful cancer surgery.

Our Non-INVASIVE technology combines electromagnetic energy in the form of microwaves and radio frequency with nanoparticles, controlled by our proprietary algorithms, to ablate tumors precisely, effectively, and in a very short time without affecting surrounding healthy tissue or leaving any cosmetic damage.



We are innovative in that we can perform noninvasive electromagnetic ablation giving us the ability to selectively treat superficial cancer tumors without damaging the surrounding healthy tissue or causing cosmetic impairment.


With this capability we can potentially treat many superficial tumors including breast, skin, tongue, thyroid, head & neck.

No costly, live-imaging guided modalities (like MRI) are needed to monitor the ablation procedure.

Our device is **versatile** and may be used not only in hospitals, but also in cancer clinics.

How Our Solution Works

Patent Filed



Nano Particles

01

- System combines different types of Electromagnetic Energy with Optical Thermal Sensing.

02

- Tumors are injected with FDA approved nanoparticles.

03

- Special electromagnetic applicators are designed and optimized to interact with the nanoparticles.

04

- The interaction of electromagnetic energy in the form of radio frequency and microwaves with nanoparticles leads to selective heating of the tumor.

05

- Heating is controlled through optimized computer algorithms.

06

- The synergistic effect of all these factors leads to maximal destruction of tumors at minimal

energies and no damage to healthy tissue.

How does SynergyMed's technology differ from traditional cancer treatments?

Competitive Analysis

Breast Cancer

Company	Technology	Non-Invasive applicator	Selective Heating	Image-guidance Unnecessary	Thermal dose Evaluation	Treat multiple tumors simultaneously	Necessary MNP Concentration
SYNERGY	RF & MW	✓	✓	✓	✓	✓	Low
Novian Health	Laser Ablation			✓	✓		N/A
Surgical Resection	BCS		N/A	N/A	N/A	✓	N/A
IceCure	Cryo-ablation						N/A
Medtronic, J&J, Boston Sci., Angiodynamics	Percutaneous, Thermal Ablation / Electroporation						N/A
Insightec	Focused US	✓	✓				N/A


*MNP=Magnetic Nanoparticles, *RF=Radio Frequency, *MW=Microwave, *US=Ultrasound, *BCS= Breast Conserving Surgery

The potential market for our product is significant.

A combined use of the technology for veterinary applications and human superficial tissue can lead to a market of over \$50 Billion.

Potential Human Market Size For Our Application

- Human Breast Cancer: \$8.6B Worldwide.
- Other relevant potential cancer tumor markets include skin, head & neck, thyroid, and palliative patients estimated from our application at \$23B



Veterinary applications and human superficial tissue can lead to a market of over \$50 Billion.

Our first go-to-market will be veterinary.




SYNERGY
MED

First Go-to-Market

Veterinary Market


Why veterinary market first?


This market **doesn't require FDA approval** for medical devices, which makes for easy entry, and allows us to start generating revenue faster. The data collected will also help us accelerate our FDA application process to expand into the human market.





Milestones





Future projections are not guaranteed




Our business model allows for the device to be sold in full or leased at a pay-per-use option, **with continuous revenue generation from consumables.**

Combined Revenue Projection

Assumptions

- Five patients treated per week per device at \$1,500 charge for consumables per procedure
- Fixed cost of consumables (\$1500)
- 2 pricing models for distribution



Future projections are not guaranteed

Letters of Interest, Partnership, and Recommendation

SYNERGY

Medtronic

This letter expresses Medtronic's interest in the development and advancement of SynergyMed's non-invasive electromagnetic ablation systems for the treatment of cancerous tumors.

In addition to being intrigued by this novel technology, I am also specifically encouraged by the early preliminary ablation results.

University of Maryland

Medtronic Surgical Innovations

Hoffitt

Boston Scientific

Boston Scientific is interested in the advancement of SynergyMed and views it as a potential partner as it advances into allied fields.

other fields of cancer. This approach potentially can be more cost effective than surgical procedures while resulting in improved outcomes compared to surgical resection and other current ablation technology. Once approved for use, I would be very much interested in bringing this technology to our cancer center and participating the Phase I clinical trial in Stage IV breast cancer patients.

Medtronic

Hoffitt

Boston Scientific

Medtronic

This letter expresses Medtronic's interest in the development and advancement of SynergyMed's non-invasive electromagnetic ablation systems for the treatment of cancerous tumors.

SynergyMed Devices Inc
240 Conant St
Danvers, MA 01923

Dear NIH SBIR Reviewing Committee,

This letter expresses Medtronic's interest in the development and advancement of SynergyMed's non-invasive electromagnetic ablation systems for the treatment of cancerous tumors.

Medtronic is a global leader in medical technology with annual sales exceeding \$30 billion USD, and a leading provider of innovative surgical products. Many of Medtronic's surgical products are used in the resection of breast cancer. One of more frequent, and in those instances costly, issues associated with these same procedures is the need for tumor re-excision. This happens when the surgeon does not properly identify and remove the entirety of the tumor in the breast at the time of the original operation.

SynergyMed is developing a novel solution designed to address this unfortunate clinical problem. The company's noninvasive ablation system is designed to replace the need for invasive surgical resection of cancerous tumors. Instead of surgery, the SynergyMed technology quickly and effectively ablates and destroys tumors without damaging healthy tissue. To date, existing ablation technologies have had limited success in breast because of challenges in executing both the safety and precision of heat transfer. SynergyMed addresses these primary issues by combining the interaction of electromagnetic energy with nanoparticles, thus creating an effect of selective heating to the tumor. Heating is further controlled through optimized computer algorithms, enabling maximal destruction of tumors while minimizing damage to healthy tissue.

SynergyMed could be of possible interest to Medtronic due to its potential to address some of the aforementioned challenges experienced in breast cancer treatment. Additional benefits may be seen in several other surgical procedures as well. But broadly speaking, the successful development of SynergyMed has the opportunity to benefit the medical community by making cancerous treatments easier and more reliable for healthcare providers, while improving outcomes for patients.

We look forward to learning more about the advancement of SynergyMed, as the company continues to progress with its development work.

Sincerely,



Geoff DaCosta
Director, Business Development & Licensing
Medtronic Surgical Innovations



other fields of cancer. This approach potentially can be more cost effective than surgical procedures while resulting in improved outcomes compared to surgical resection and other current ablation technology. Once approved for use, I would be very much interested in bringing this technology to our cancer center and participating the Phase I clinical trial in Stage IV breast cancer patients.

To Whom It May Concern:

I am a Senior Member at Moffitt Cancer Center and Professor of Surgery at the University of South Florida with expertise in Surgical Breast Oncology. My research interests are selecting patients for breast conserving surgery and studying the patterns of recurrence. I am also the chair of education in the breast department and director of Society of Surgical Oncology accredited breast fellowship.

I am writing this strong letter in support of the advancement of SynergyMed's medical devices' unique noninvasive alternative to surgical resection of tumors. This technology replaces the need for invasive surgical resection without the risk of cosmetic and surgical morbidity. SynergyMed's noninvasive ablation system effectively ablates tumors without damaging healthy tissue. This technology and research will not only revolutionize breast cancer treatment but can also contribute to other fields of cancer. This approach potentially can be more cost effective than surgical procedures while resulting in improved outcomes compared to surgical resection and other current ablation technology. Once approved for use, I would be very much interested in bringing this technology to our cancer center and participating the Phase I clinical trial in Stage IV breast cancer patients.

I fully support and encourage the committee to fund this innovative research proposal to assist in the advancement of SynergyMed.

Sincerely,



Nazanin Khakpour, MD, FACS
Senior Member
Surgical Oncologist
Department of Breast Oncology
Moffitt Cancer Center

12802 MAGNOLIA DRIVE, TAMPA, FL 33612-9416 | 1-888-MOFFITT | MOFFITT.ORG

H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE | AN NCI DESIGNATED COMPREHENSIVE CANCER CENTER

Due Diligence

Our company has been vetted and qualified

by various grantors and venture capitalists (VCs). Through rigorous due diligence with these institutions, we were awarded several prizes and grants, including:

- Merage (Orange County, California) Institute +45 Competition: Won the second prize out of 400 medical device startups.
- Russia (Moscow): Won the Gold Medal of the Archimedes conference of science and technology amongst 27 countries.
- World Economic Forum: Company chosen in the top 100 startups.
- New England Venture Summit (Boston): Chosen amongst the top 20 medical device companies to present at the summit.

SYNERGY

Seeking

\$500K in crowdfunding

(Coupled with an existing \$200K in grant money)

01

**Dog Clinical Studies
and Pre-Clinical
preparation for the
FDA**

02


**Veterinary Device
Ready of Sale**

03

**Human Device Ready
for Clinical Studies**

How are we going to use the money?

Use of Funds



Our crowd-funding goals aim to:

- (1) publicly advertise the company and its product
- (2) give our friends and network access to investing in our startup
- (3) help us reach our milestones swiftly and smoothly

Executive Team

Experience from leading corporate and academic institutions



Anan Copty, Ph.D.

Founder & CEO

25+ years of technical & leadership experiences, RMD: Radiation Monitoring Devices, Intel: Biochips, Harvard Medical School: MRI

Daniel Kacher, Ph.D.

Director of Clinical Studies and Product Development

Ph.D. in Biomedical Engineering
25 years at Brigham and Women's Hospital

Mimi Copty, MHA

COO

25+ years of project management & leadership experiences in health organizations in the US and internationally

Robert Roy, MBA, BSEE/BSME

VP of Marketing, Sales

35+ years of senior-level management in medical device companies

Yahya Dajani

VP of Business & Customer Development

Medical Technology Entrepreneur. Co-founded NCA Monitoring Technologies & D&O LLC
ADNOC Oil Company
Corporate Planning, Finance, Performance, and Business Development

Acknowledgement and Resources

Medical Advisors

Practicing oncologists with international reputations and numerous high impact journal publications



Prof. Nader Hanna, MD

Chief of Surgical Oncology
Jefferson University, Pennsylvania



Dr. Salem Billan, MD

Director of Head & Neck Oncology Unit Rambam Medical Center in Haifa



Dr. Wasim Geraisy, DVM

Owner of Waza Pets Center
15 years of experience in treating dogs, cats and horses
Leads and trains several veterinary doctors



Rand Arafeh, Ph.D.

Pre-Clinical Studies Development
Ph.D. in Cancer Biology
Harvard Medical School post-doc

We are an experienced team of MTM management, technical, and medical leaders with backgrounds from leading corporate and academic institutions.

**Join us in the fight to make
Effective Treatment Accessible!
Invest Today!**

